Engflag

Lita

Quick links to important sections

Lita

Lita_EN

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lita

What is Lita? Defining the Drug's Identity

Property Description
Active Ingredient Pioglitazone Hydrochloride
Form Oral Tablet
Pharmacological Class Thiazolidinedione, Antidiabetic Agent
General Purpose Management of elevated blood sugar levels
Origin Synthetic Compound

What Type of Medicine is Lita (Pioglitazone)?

Lita is a prescription-only antidiabetic agent used to help manage the metabolic disorder Type 2 Diabetes Mellitus. Its active component is Pioglitazone, which chemically belongs to the class of medications known as thiazolidinediones (TZDs).

Lita is a synthetic compound, chemically manufactured to provide a specific therapeutic effect in the body. This compound is clinically recognized for its focused role in addressing metabolic dysfunction. As an oral preparation, it is classified as a specific type of oral hypoglycemic, a category of drugs taken by mouth to help lower or control elevated blood sugar levels. Pioglitazone exerts its primary effect as a potent ligand for PPARgamma.

Composition and Physical Form of Lita

Lita is a single-component product administered as an oral tablet and contains the active ingredient Pioglitazone Hydrochloride.

The formulation of Lita is designed for oral administration, ensuring the active substance is absorbed systemically via the gastrointestinal tract. The tablet is composed of the Pioglitazone Hydrochloride—the pharmacologically active salt form—combined with solid pharmaceutical excipients that facilitate consistent drug delivery. Pioglitazone is indicated for the treatment of Type 2 Diabetes Mellitus.

General Purpose: How Lita Manages Blood Sugar

The general therapeutic purpose of Lita is to achieve and maintain better glycemic control by acting as an insulin sensitizer.

Lita's primary function is to directly target and improve the body's response to the insulin it already produces. By reducing cellular insulin resistance in tissues like fat and muscle, Lita makes these cells more receptive to insulin signals, thereby enhancing their ability to take up and utilize glucose from the bloodstream. Insulin sensitizers are recognized for improving insulin action in patients with Type 2 Diabetes.

Regulatory References

  1. FDA Prescribing Information for Pioglitazone

What side effects are possible with Lita?

Possible Side Effects and Safety Information

The safety profile of Lita (Pioglitazone) is based on classifications from official regulatory documents. Adverse reactions are grouped by frequency and the body system affected, addressing the officially documented risk profile of the medicine.

Official Adverse Reactions and System Classification

Adverse reactions classified as Common (observed in 1% to 10% of patients) include headache, upper respiratory tract infection, weight gain, and edema (fluid retention). Visual disturbance and myalgia (muscle pain) are also listed among common effects. The regulatory framework notes that the frequency of low blood sugar (hypoglycemia) is higher when Lita is used in combination with other antidiabetic agents.

Serious Safety Concerns and Restrictions

Official labeling highlights several significant safety considerations:

  • Congestive Heart Failure: Pioglitazone may cause or exacerbate fluid retention, which can lead to or worsen congestive heart failure (CHF). The medicine is contraindicated (should not be used) in patients with established New York Heart Association (NYHA) Class III or IV heart failure.
  • Bladder Cancer: Regulatory reviews suggest a small increased risk of bladder cancer, particularly associated with long-term exposure (e.g., greater than one year).
  • Bone Fracture: An increased risk of bone fractures has been specifically documented in female patients taking Pioglitazone.

Additionally, the label notes that Lita should not be initiated in individuals with active liver disease or significantly elevated baseline liver enzymes.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based solely on regulatory documentation outlining the management and presentation of Pioglitazone overdosage.

Overdose Manifestations and Immediate Action

Feature Official Regulatory Guidance
Documented Overdose Presentations A reported case of acute overexposure, involving doses significantly exceeding the maximum recommended limit, found that the patient denied experiencing any clinical symptoms in the official record.
Required Emergency Action For a known or suspected overdosage, it is mandated to seek immediate medical attention or contact emergency services and a Poison Control Center without delay.
Antidote Information Regulatory prescribing information explicitly states that no specific antidote is known for Pioglitazone overdosage.

Management and Monitoring

Feature Official Regulatory Guidance
Symptomatic Management Treatment should involve the initiation of appropriate symptomatic and supportive treatment based on the patient's immediate clinical presentation and signs.
Elimination Constraints The active substance is highly bound to plasma proteins, confirming that standard procedures such as dialysis are ineffective for increasing the elimination of Pioglitazone from the body.
Observation Requirement Following overdosage, patients must be observed carefully for any clinical signs and symptoms that may emerge.

The official overdose profile emphasizes that immediate medical consultation is required for any accidental or intentional exposure exceeding the prescribed limit, regardless of the patient’s initial apparent health status. This cautious approach is driven by the lack of a specific antidote and the inability to remove the substance via dialysis.

Therapeutic Uses of Lita

What Lita Treats: Main Uses and Benefits

Lita is commonly used in the therapeutic domain of Type 2 Diabetes Mellitus to address symptoms related to systemic imbalance that define the condition. It plays a role in managing these symptoms over time and is frequently utilized to help with physical discomfort caused by such imbalances.

Primary Therapeutic Scope

The primary therapeutic benefit is its role in managing symptoms related to chronic high blood sugar and addressing functional stability affected by insulin insensitivity. It may also be part of symptomatic management for high-risk patients with pre-existing macrovascular disease or prior stroke.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

This medicine is commonly used to help with managing symptom clusters that may become intense or disruptive, particularly when applied in conditions where functional stability becomes affected. It contributes to easing the overall symptom load by assisting with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Lita is indicated for use exclusively in adults with Type 2 Diabetes Mellitus.

Populations Who Must Not Use Lita (Contraindications)

Use of Lita is strictly prohibited based on governmental regulatory labeling in patients with the following conditions:

  • Established NYHA Class III or IV heart failure (or any history of heart failure, per some regional labels).
  • Active bladder cancer or uninvestigated macroscopic haematuria.
  • Hepatic impairment (liver dysfunction).
  • Type 1 Diabetes Mellitus or diabetic ketoacidosis.
  • Known hypersensitivity to pioglitazone or any component of the formulation.

Eligibility-Related Restrictions

Population/Condition Regulatory Status
Pediatric Patients (under 18) Not recommended; safety and efficacy are not established.
Pregnancy/Lactation Should not be used during pregnancy; use during breastfeeding is not recommended.
Prior History of Bladder Cancer Use requires caution; the benefit must be weighed against potential risk.
Patients on Dialysis Not recommended due to lack of available data.
Premenopausal Females Use may increase the chance of unintended pregnancy due to potential ovulation induction.

Eligibility is defined by the absence of these specific, officially documented medical conditions and is limited to the adult population with Type 2 Diabetes.

What should I know about interactions with other medicines?

The official interaction profile for Lita (axitinib) is predominantly defined by its metabolism through the CYP3A4/5 enzyme pathway, which governs how the body clears the drug. This structure leads to specific regulatory constraints on co-administered substances.

Interactions with Other Products

Substance Category Interaction Effect (Regulatory Basis) Restriction
Strong CYP3A4/5 Inhibitors (e.g., ketoconazole) Significantly increases Lita's plasma exposure Avoid combination; use is unavoidable, a dose reduction is required.
Strong CYP3A4/5 Inducers (e.g., rifampin, phenytoin) Significantly decreases Lita's plasma exposure Avoid combination; may render the drug less effective.
Herbal/Food Products (e.g., St. John's wort, Grapefruit) St. John's wort induces CYP3A4/5; Grapefruit inhibits CYP3A4 Avoid St. John's wort and grapefruit/grapefruit juice.

Population-Specific Interaction Notes

Patients with moderate hepatic impairment (Child-Pugh Class B) exhibit increased systemic drug exposure. This intrinsic factor officially necessitates a reduced starting dose. The drug has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).

Regulatory Context

The regulatory profile emphasizes that co-administration with products that modify the CYP3A4/5 enzyme system must be restricted to manage the risk of potentially harmful increases or clinically significant decreases in drug concentration. These guidelines define the boundaries for safe co-administration.

Mechanism of Action

How Lita Works: Mechanism of Action

Lita operates as an agonist that selectively binds to the Peroxisome Proliferator-Activated Receptor gamma (PPAR gamma), a nuclear receptor primarily expressed in adipose (fat), muscle, and liver cells. This molecular interaction initiates the transcription of specific genes involved in metabolic regulation, altering the cellular response to nutrient handling.

This genetic modulation leads to a cascade that alters cellular sensitivity to existing insulin by enhancing the expression and translocation of glucose transporters to the cell membrane. Consequently, the uptake and utilization of glucose by peripheral tissues is increased. Simultaneously, Lita influences the liver by suppressing the activity of key enzymes required for gluconeogenesis. This targeted action reduces the rate at which the liver releases new glucose into the circulation, which in turn influences the overall regulation of circulating glucose levels.

Dosage and Administration Information

How Lita (Pioglitazone) is Used: Administration Guidelines

Lita (Pioglitazone) is administered as an oral tablet for once-daily dosing. The usage principles are defined by established guidelines.

Official Dosing and Scheduling

Parameter Administration Instruction
Route of Administration Oral only. The tablet should be swallowed whole with water.
Available Strengths 15 mg, 30 mg, and 45 mg tablets.
Standard Starting Dose 15 mg or 30 mg once daily. The starting dose should be 15 mg once daily for patients with New York Heart Association (NYHA) Class I or II heart failure.
Maximum Daily Dose 45 mg once daily.
Timing Relative to Meals May be taken with or without food.
Long-Term Review Treatment must be reviewed after three to six months to assess response, and discontinued if inadequate.

Population-Specific Use

Dosage adjustments are required in certain circumstances as mandated by regulatory guidelines:

  • CYP2C8 Inhibitors: When Lita is co-administered with strong inhibitors of CYP2C8 (e.g., gemfibrozil), the maximum recommended dose must be limited to 15 mg daily.
  • Older Adults: Treatment should be initiated at the lowest available dose (15 mg), and the dose should be increased gradually, especially when used in combination with insulin.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Lita

The research on Lita (Pioglitazone) focuses on its evaluation in clinical settings, primarily for the evaluation of blood sugar control and exploring its potential role in secondary prevention of major cardiovascular events in high-risk scenarios. The evidence is drawn from numerous controlled trials and long-term observational studies, which help show what has been observed so far, but do not provide individual predictions. Research findings reflect the specific methods and participant cohorts under which the studies were conducted.

Evidence for Glycemic Control in Type 2 Diabetes Mellitus

The most extensive research for Lita has been conducted to evaluate blood sugar control in adults with Type 2 Diabetes Mellitus (T2DM). Researchers primarily used Randomized Controlled Trials (RCTs) to evaluate Lita, often comparing it against placebo or other established antidiabetic agents.

In these studies, research examined changes in key blood markers, such as Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG), which are used as indicators of overall blood sugar control. Across various RCTs, studies reported consistent changes in the measured surrogate endpoints, such as reductions in mean HbA1c levels over the study period. The research provides context on short-term changes in these biomarkers, but the long-term characteristics of the measured outcomes are not always well characterized by the available evidence.

Evidence for Managing Macrovascular Risk in High-Risk Patients

Lita has also was studied for a role in secondary prevention—that is, exploring its potential role in secondary prevention of major cardiovascular events in patients with T2DM who already had a history of a prior event. This research involved large-scale, long-term Randomized Controlled Trials.

Findings indicate patterns related to the risk of recurrent stroke events, as some trials described observations where participants who received Lita had fewer fatal or non-fatal recurrent stroke events compared to the placebo group. However, the primary composite outcome of major events did not meet the statistical threshold set by the researchers in the key long-term trial, which contributes to scientific discussion regarding the overall pattern of macrovascular outcomes.

Key Studies & References

  1. ACTOS® (pioglitazone hydrochloride) Tablets Full Prescribing Information
  2. NICE guideline [NG28] - Type 2 diabetes in adults: management (2022 update)

Frequently Asked Questions (FAQ)

Common questions about Lita (FAQ)

Q: Does Lita help me lose or gain weight?

Studies and official information indicate that weight gain is a common side effect of Lita. This weight gain has been shown to be dose-related and may be a result of fat accumulation. In some cases, it may also be associated with fluid retention.

Q: What should I do if I forget to take my Lita dose?

Official product information states that if a dose is missed, the medicine should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the next dose is taken at the regular time. Double or extra doses are not intended to compensate for the missed dose.

Q: How exactly does Lita increase my body’s sensitivity to insulin?

Lita works by acting as an agonist for a receptor inside cells called PPARgamma (Peroxisome Proliferator-Activated Receptor gamma). This action is mainly observed in fat, muscle, and liver tissues. This mechanism is intended to enhance the effects of existing insulin by reducing insulin resistance in peripheral tissues, which supports the lowering of blood sugar levels.

Q: Is Lita a good choice for someone newly diagnosed with Type 2 Diabetes?

According to official regulatory documents, Lita is indicated for adults with Type 2 Diabetes Mellitus to improve blood sugar control alongside diet and exercise. It can be used by itself (monotherapy) or combined with other diabetes medicines. The suitability of this medication for an individual patient must be determined by a healthcare professional.

How should Lita be stored and disposed of?

How to Store and Dispose of Lita (Pioglitazone Hydrochloride)

Storage of Lita tablets must strictly adhere to regulatory requirements to ensure product stability and effectiveness.

Storage Conditions

Requirement Official Instructions
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection Keep protected from light, moisture, and excess heat.
Container Keep in the original container with the cap tightly closed.
Safety Must be stored out of the reach of children.

Disposal

Unused or expired tablets should be disposed of in accordance with official procedures. It is recommended to use a medicine take-back program when available. Lita should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Lita found in:

A-Z Index: